Frank Lieberman

Edwin Lok1
Kenneth D Swanson1
1Edwin Lok
1Kenneth D Swanson
Learn More
The NovoTTF-100A device emits frequency-tuned alternating electric fields that interfere with tumor cell mitosis. In phase III trial for recurrent glioblastomas, NovoTTF-100A was shown to have equivalent efficacy and less toxicity when compared to Best Physician's Choice (BPC) chemotherapy. We analyzed the characteristics of responders and nonresponders in(More)
  • 1